Reduced COVID-19 vaccine response in patient treated with dupilumab for IgG4-related disease

Armin Abadeh,Jason Kihyuk Lee

Journal of Allergy and Clinical Immunology: Global（2023）

Cited 0|Views1
No score
Abstract
Dupilumab is a novel anti-IL-4 receptor-α mAb that targets the signaling pathways of IL-4 and IL-13. Thus far, the data about adequate humoral immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients who are taking dupilumab have been limited.
More
Translated text
Key words
Dupilumab,IgG4,COVID-19,vaccination
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined